SCHEMBL6153141

SCHEMBL6153141

COC(=O)CC(=O)CCc1ccccc1CO[Si](C)(C)C(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.46
LMNA P02545 3/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP4F2 P78329 1/20 0.36
CYP4A11 Q02928 1/20 0.36
TSHR P16473 1/20 0.35
MTNR1A P48039 1/20 0.35
MTNR1B P49286 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
KDM4E B2RXH2 3/20 0.33
TACR1 P25103 1/20 0.33
CCNC P24863 1/20 0.33
CDK8 P49336 1/20 0.33
F2RL1 P55085 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7242193 0.83 MTNR1A (0.39) LMNAALDH1A1TSHRMTNR1AMTNR1B
SCHEMBL6296347 0.81 BACE1 (0.41) BACE1MTNR1AMTNR1B
SCHEMBL6296565 0.80 BACE1 (0.46) BACE1LMNAALDH1A1CYP4F2CYP4A11
SCHEMBL6152498 0.75 ALDH1A1 (0.43) LMNAALDH1A1CYP4F2CYP4A11TSHR
SCHEMBL25591913 0.74 ALDH1A1 (0.50) BACE1LMNAALDH1A1TSHRKDM4E
SCHEMBL10140463 0.73 CYP4F2 (0.40) BACE1LMNAALDH1A1CYP4F2CYP4A11
SCHEMBL2750402 0.73 BACE1 (0.47) BACE1CYP4F2CYP4A11TACR1
SCHEMBL6933016 0.72 ALDH1A1 (0.51) LMNAALDH1A1CYP4F2CYP4A11TSHR
SCHEMBL6153056 0.72 BACE1 (0.40) BACE1LMNAALDH1A1TSHR
SCHEMBL7532530 0.72 BACE1 (0.36) BACE1ALDH1A1MTNR1AMTNR1BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1307449-B1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMA (JP) 2005-12-07 EP disclosed
US-6653313-B2 For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders WARNER-LAMBERT COMPANY LLC 2003-11-25 US disclosed
EP-1307449-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2003-05-07 EP disclosed
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists KAWAMURA MITSUHIRO (US) 2002-10-31 US disclosed
WO-2002012235-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists BDKRB1, BDKRB2, HRH4 BACE1 2048/4885LMNA 3127/4885ALDH1A1 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.